LAT CAB Brochure

By Ana Balkandjieva

1 February 2023

Long-acting technologies

Learn about LAT CAB, Longevity project and meet the LAT CAB community experts.

Attached documents

Related materials

LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, HIV, and LTBI. More

8 August 2024CABs LAT CAB (2021-present)

Illustrated Glossary for LATs

The Glossary compiles frequent terms and concepts used in the research and development of long-acting technologies. More

19 September 2021CABs LAT CAB (2021-present)

Medicines Patent Pool Secures its First Licence on Promising Long-Acting Technologies for Malaria, TB, and Hepatitis C

The licence covers the patents and expertise of promising long-acting injectable technologies that could be applied in three disease areas with a high prevalence in LMICs. More

21 September 2021CABs LAT CAB (2021-present)

TAGline: Delivering on the Promise of Long-Acting Formulations

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria. More

7 October 2021CABs LAT CAB (2021-present)

Hepatitis C and TB Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

A patent landscape, released by TAG, investigates potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines. More

14 November 2021CABs LAT CAB (2021-present)

Call for New Global Long-Acting Technologies CAB Members from Asian, Central African, Eastern European, MENA, and Latin American Countries

TAG and AfroCAB announce an expanded call for a new cross-disease LAT CAB focused on malaria, hepatitis C, and latent TB. Apply now! Applications accepted on a rolling basis. More

24 January 2022CABs LAT CAB (2021-present)